<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Placenta previa: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Placenta previa: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Placenta previa: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen Russo-Stieglitz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vincenzo Berghella, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 31, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Placenta previa refers to the presence of placental tissue that extends over the internal cervical os. Because this can lead to severe antepartum, intrapartum, and/or postpartum bleeding, placenta previa is associated with high risks for preterm birth and maternal and fetal/neonatal morbidity.
        </p>
        <p>
         The management of pregnancies complicated by placenta previa is best addressed in terms of the patient's clinical setting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active antepartum bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stable after one or more episodes of active antepartum bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postpartum hemorrhage
        </p>
        <p>
        </p>
        <p>
         This topic will discuss the management of these patients. The epidemiology, clinical features, diagnosis, morbidity, and mortality of placenta previa are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ASYMPTOMATIC PATIENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3240118738">
         <span class="h2">
          Goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main goals during management of asymptomatic patients are to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determine whether the previa resolves with increasing gestational age
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determine whether the placenta is also morbidly adherent (placenta accreta spectrum)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduce the risk of bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determine the optimal time for planned cesarean birth if the previa persists
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4763313">
         <span class="h2">
          Monitoring placental position
         </span>
         <span class="headingEndMark">
          —
         </span>
         Follow-up transvaginal ultrasound examination of placental position is indicated when the placenta covers or is &lt;2 cm from the internal os on a second-trimester ultrasound examination. (See
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality", section on 'Asymptomatic finding on midtrimester ultrasound examination'
         </a>
         .)
        </p>
        <p>
         We agree with the consensus approach of an expert group for monitoring placental position of these pregnancies  (
         <a class="graphic graphic_algorithm graphicRef115747" href="/z/d/graphic/115747.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the placental edge covers or is &lt;2 cm from the internal os in the second trimester, follow-up transvaginal ultrasonography for placental position is indicated at 32 weeks of gestation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At the 32-week follow-up examination:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the placental edge is ≥2 cm from the internal os, the placental position is reported as normal and additional follow-up ultrasound examinations for placental position are not indicated. (See
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality", section on 'Asymptomatic finding on midtrimester ultrasound examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Color and pulsed Doppler examinations are useful to confirm the position of the placental edge and rule out vasa previa, which may result from resolution of a low-lying placenta. (See
         <a class="medical medical_review" href="/z/d/html/6807.html" rel="external">
          "Velamentous umbilical cord insertion and vasa previa"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the placental edge covers or is &lt;2 cm from the internal os, a follow-up transvaginal ultrasound for placental position is indicated at 36 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At the 36-week follow-up examination:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the placental edge covers the internal os, cesarean birth is scheduled, as the previa is likely to persist until the time of birth. (See
         <a class="local">
          'Timing of delivery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the placental edge does not cover but is &lt;2 cm from the internal os, the risks and benefits of a trial of labor should be discussed with the patient. The risk of bleeding increases as the distance between the placental edge and internal os decreases and if vasa previa is present. (See
         <a class="local">
          'Timing of delivery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H706600188">
         <span class="h2">
          Excluding placenta accreta spectrum
         </span>
         <span class="headingEndMark">
          —
         </span>
         The possibility of placenta accreta spectrum (PAS) should be excluded in all patients with placenta previa, given the strong association between the two disorders. (See
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality", section on 'Placenta previa-accreta spectrum'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">
          "Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences", section on 'Prenatal diagnosis'
         </a>
         .)
        </p>
        <p>
         If present, antepartum management of PAS is the same as for placenta previa, but delivery risks are substantially greater. Cesarean birth is scheduled earlier in gestation (34+0 to 35+6 weeks of gestation) than for previa alone, and preoperative preparation includes planning for cesarean-hysterectomy (which is usually required) and interventions that will reduce the risk of massive hemorrhage (which is more common than with previa alone). (See
         <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">
          "Placenta accreta spectrum: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1692802564">
         <span class="h2">
          Reducing the risk of bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         For an individual patient, it is not possible to accurately predict whether spontaneous bleeding will occur, the gestational age when it will start, the volume, or the duration and frequency of bleeding events. Sonographic features reported to be associated with a higher likelihood of antepartum bleeding are described separately. (See
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality", section on 'Bleeding'
         </a>
         .)
        </p>
        <p>
         Interventions have been proposed to reduce the risk of bleeding:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is consensus that digital cervical examination should be avoided. It is clear from anecdotal experience that palpation of a placenta previa through a partially dilated cervix can result in severe hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We advise patients with placenta previa after 20 weeks of gestation (earlier if they have experienced vaginal bleeding) to avoid any sexual activity that may lead to orgasm. The rationale is that this activity, especially if orgasm occurs, may be associated with transient uterine contractions, which, in turn, may provoke bleeding. Additionally, there is concern that vaginal intercourse (or putting any object deep into the vagina) might cause direct trauma to the previa, resulting in bleeding. There are no published studies that either support or refute this advice. It is extrapolated from observations that palpation of the previa through a partially dilated cervix can result in severe hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We also advise patients with placenta previa after 20 weeks to avoid moderate and strenuous exercise, heavy lifting (eg, more than approximately 20 pounds), or standing for prolonged periods of time (eg, &gt;4 hours). In the general obstetric population, this degree of activity was linked to small but statistically significant increases in preterm birth in a meta-analysis of observational studies (median odds ratios 1.10 to 1.20) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition, we advise patients to seek immediate medical attention if contractions or vaginal bleeding occur, given the potential for severe bleeding and need for emergency cesarean birth.
        </p>
        <p class="headingAnchor" id="H1871949227">
         <span class="h2">
          Inpatient versus outpatient monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether asymptomatic patients benefit from hospitalization is unclear. Findings from observational studies suggest that patients who have not experienced any antepartum bleeding are at low risk of sudden hemorrhage requiring an emergency cesarean birth for control of bleeding [
         <a href="#rid3">
          3-6
         </a>
         ]. Therefore, it is likely that most of these patients can be managed on an outpatient basis until vaginal bleeding occurs or until admission for scheduled cesarean birth.
        </p>
        <p>
         However, patient-specific risk factors need to be taken into account. Such factors may include [
         <a href="#rid7">
          7-9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short cervical length on transvaginal ultrasound examination (eg, there is an increased risk for preterm labor if cervical length is ≤25 mm, and we consider hospitalization if ≤15 mm)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid cervical shortening (eg, &gt;10 mm over a one- to two-week period on transvaginal ultrasound)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inability to get to the hospital promptly (within approximately 20 minutes), and lack of home support in case of an emergency
        </p>
        <p>
        </p>
        <p>
         These parameters, which are based on personal clinical experience/expert opinion and data from studies on risk of preterm birth across the spectrum of cervical length, represent our approach and should not be considered a standard of care. The Society for Maternal-Fetal Medicine recommends not routinely performing cervical length screening in the late preterm period in patients with placenta previa due to a lack of data on an appropriate management strategy [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3570594046">
         <span class="h2">
          Antenatal corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have not received a course of antenatal corticosteroids for standard obstetric indications at some point during the pregnancy, we administer a course 48 hours before a planned cesarean birth scheduled for &lt;37+0 weeks of gestation. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on 'Candidates for a first ACS course by gestational age'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4766607">
         <span class="h2">
          Timing of delivery
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform a cesarean birth at 36+0 to 37+6
         <sup>
         </sup>
         weeks of gestation in pregnancies with uncomplicated placenta previa, in agreement with recommendations of the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine [
         <a href="#rid10">
          10,11
         </a>
         ]. Uncomplicated placenta previa is defined as without fetal growth restriction, superimposed preeclampsia, or other issues that take precedent for delivery decision-making.
        </p>
        <p>
         Review of available evidence suggests that the maternal-fetal risks associated with continuing the pregnancy (severe bleeding, emergency unscheduled delivery) are greater than the neonatal risks associated with preterm birth at this gestational age range. (See
         <a class="local">
          'Cesarean birth'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ACUTE CARE OF BLEEDING PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         An actively bleeding placenta previa is a potential obstetric emergency. These patients should be admitted to the Labor and Delivery Unit for maternal and fetal monitoring, and the anesthesia team should be notified.
        </p>
        <p class="headingAnchor" id="H441961723">
         <span class="h2">
          Goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major goals in managing a patient with an acutely bleeding placenta previa are to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Achieve and/or maintain maternal hemodynamic stability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determine if emergency cesarean birth is indicated
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4767361">
         <span class="h2">
          Maternal and fetal assessment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal blood pressure, heart rate, respiratory rate, peripheral oxygen saturation, and urine output are closely monitored. Tachypnea, tachycardia, hypotension, low oxygen saturation, and air hunger are signs of hypovolemia  (
         <a class="graphic graphic_table graphicRef56885" href="/z/d/graphic/56885.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The fetal heart rate is monitored continuously for patterns suggestive of hypoxemia or anemia. (See
         <a class="medical medical_review" href="/z/d/html/16663.html" rel="external">
          "Intrapartum category I, II, and III fetal heart rate tracings: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood loss is quantified. The accuracy of blood loss assessment is improved with quantitative measurement techniques [
         <a href="#rid12">
          12
         </a>
         ]. Accurate estimation of vaginal blood loss is difficult to determine visually, particularly when blood is partially saturating or soaking towels, maternity pads, or gauze sponges or dripping onto the floor [
         <a href="#rid13">
          13,14
         </a>
         ]. One or more of the following techniques can be used to quantify blood loss [
         <a href="#rid14">
          14,15
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Collect blood in graduated volumetric containers.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Measure the total weight of bloody materials and subtract the known weight of the same materials when dry. The difference in weight between wet and dry in grams approximates the volume of blood in milliliters.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Attempt to account for fluids other than blood (eg, amniotic fluid, irrigation fluid, urine) that are collected or absorbed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use visual aids that correlate the size and appearance of blood on specific surfaces (eg, maternity pad, emesis basin, bed sheet, lap sponge) with the volume of blood absorbed by that surface  (
         <a class="graphic graphic_picture graphicRef103418" href="/z/d/graphic/103418.html" rel="external">
          picture 1
         </a>
         ). Regularly scheduling standardized training in the use of these charts can be helpful for this assessment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the data do not support any one method of quantifying blood loss as superior to another, quantification of blood loss, such as using graduated drapes or weighing, provides a more accurate assessment of actual blood loss than visual estimation; however, the effectiveness of quantitative blood loss measurement on clinical outcomes has not been demonstrated [
         <a href="#rid16">
          16-18
         </a>
         ]. Successful implementation of an obstetric hemorrhage bundle has been associated with improved outcome measures related to obstetric hemorrhage [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Laboratory testing and notifying the blood bank
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus about the components of routine laboratory assessment of patients with bleeding placenta previa [
         <a href="#rid20">
          20,21
         </a>
         ]. We do the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain a complete blood count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Send blood sample for type and antibody screen and notify the blood bank that a patient with bleeding placenta previa has been admitted. We cross-match two to four units of packed red blood cells when bleeding is heavy or increasing, delivery is likely for any reason, or difficulty in procuring compatible blood is anticipated. If massive transfusion might be needed, the blood bank is notified of that as well and a massive transfusion protocol is initiated, if available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluate for coagulopathy (fibrinogen level, activated partial thromboplastin time, prothrombin time) in patients suspected of coexistent abruption or with severe blood loss resulting in hemodynamic instability. If available, thromboelastography of whole blood at the point of care synthesizes information obtained from multiple coagulation tests into a single readout providing information regarding clot initiation, clot strength, and fibrinolysis simultaneously. (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prolonged oozing from needle puncture sites also suggests coagulopathy. A crude test for identifying patients with impaired clotting function can be performed at the bedside using blood in a red top tube (clot observation test) (see
         <a class="medical medical_review" href="/z/d/html/4460.html" rel="external">
          "Disseminated intravascular coagulation (DIC) during pregnancy: Clinical findings, etiology, and diagnosis", section on 'Diagnostic evaluation'
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Fetal bleeding can occur if disruption of fetal vessels in placental villi, vasa previa, or a velamentous cord occurs, and can be detected by performing a Kleihauer-Betke or flow cytometry test on a specimen of vaginal blood. However, fetal bleeding from disruption of one of these sources is rare and typically results in fetal demise or a nonreassuring fetal heart rate tracing necessitating emergency delivery. Therefore, it is unlikely that results of the test will impact management. (See
         <a class="medical medical_review" href="/z/d/html/6806.html" rel="external">
          "Spontaneous massive fetomaternal hemorrhage", section on 'Kleihauer-Betke assay'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2478183214">
         <span class="h2">
          Stabilization
         </span>
        </p>
        <p class="headingAnchor" id="H4767312">
         <span class="h3">
          Intravenous access and crystalloid
         </span>
         <span class="headingEndMark">
          —
         </span>
         One or two large bore intravenous lines are inserted and crystalloid (
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          Lactated Ringer
         </a>
         solution or normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ) is infused to achieve/maintain hemodynamic stability and adequate urine output (at least 30 mL/hour). (See
         <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">
          "Treatment of severe hypovolemia or hypovolemic shock in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4766979">
         <span class="h3">
          Transfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfusion of blood products in patients with active bleeding should be guided by the volume of blood loss over time, changes in hemodynamic parameters (eg, blood pressure, maternal and fetal heart rates, peripheral perfusion, and urine output), coagulation studies, and hemoglobin level. Not getting behind in replacement of blood products is essential. Acute hemorrhage may not be associated with an immediate reduction in either blood pressure or hematocrit in an otherwise healthy young patient. Thus, we have a low threshold for transfusing symptomatic patients. We believe a failure to rapidly correct tachycardia or hypotension with a normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         bolus or a hemoglobin value &lt;10 g/dL should prompt immediate transfusion. Types and actions of blood replacement products are shown in the table  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Our general approach is as follows. We do not administer tocolytic drugs to actively bleeding patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initially, we suggest transfusing two to four units of typed and crossed packed RBC, without fresh frozen plasma or platelets as long as the fibrinogen level is &gt;250 mg/dL and the platelet count is &gt;100,000/microL. Our goal is a final hemoglobin value &gt;10 g/dL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient fails to stabilize, we initiate a massive transfusion protocol  (
         <a class="graphic graphic_algorithm graphicRef91236" href="/z/d/graphic/91236.html" rel="external">
          algorithm 2
         </a>
         ). If a massive transfusion protocol is not available, type O RhD-negative blood should be administered until type-specific or typed and cross-matched blood is available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient continues to bleed, we suggest using the same blood product transfusion ratios used for patients with severe hemorrhage of other etiologies: a 1:1:1 ratio of packed RBC:fresh frozen plasma:platelets. If available, thromboelastography (TEG) or rotational thromboelastometry (ROTEM)-based transfusion algorithms may be helpful. (See
         <a class="medical medical_review" href="/z/d/html/112610.html" rel="external">
          "Intraoperative transfusion and administration of clotting factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is no imminent need for delivery, we continue transfusion until the patient has stabilized, bleeding is decreased, and hemoglobin is at least 10 g/dL. We choose this hemoglobin threshold to provide a margin of safety since the patient is at increased risk for another, more severe bleeding event. However, if there is an imminent need for delivery, a preoperative or intraoperative target hemoglobin of about 8 g/dL is reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         is generally not administered before delivery because it freely crosses the placenta. However, it has been recommended for treatment of antepartum and intrapartum bleeding related to several inherited bleeding disorders [
         <a href="#rid22">
          22
         </a>
         ] and one UpToDate contributor sometimes administers it prophylactically at the start of cesarean delivery. Fetal/neonatal harm has not been reported, but data are limited. It is commonly used as a component of treatment of postpartum hemorrhage but prophylactic use is less common. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer tranexamic acid'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4437.html" rel="external">
          "Management of the third stage of labor: Prophylactic pharmacotherapy to minimize hemorrhage", section on 'Tranexamic acid'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In low resource settings, non-pneumatic anti-shock garments have been used to restore adequate blood pressure in pregnant/postpartum patients who are hemodynamically unstable due to severe bleeding [
         <a href="#rid23">
          23-25
         </a>
         ]. These devices have not been used when the fetus was viable and there is no information on their effect on uteroplacental blood flow and the fetus. An unfavorable effect is likely since in postpartum patients these garments force blood to the essential organs, such as the heart, lungs, and brain, and significantly increase the resistive index of the internal iliac artery, which is responsible for supplying the majority of uterine blood flow [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4199786645">
         <span class="h2">
          Outcome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients who initially present with symptomatic placenta previa respond to supportive therapy, as described above, and do not require immediate delivery [
         <a href="#rid27">
          27-31
         </a>
         ]. In observational series, 50 percent of patients with a symptomatic previa (any amount of bleeding) were not delivered for at least four weeks [
         <a href="#rid28">
          28,30,31
         </a>
         ]. Even a large bleed does not preclude conservative management. In one series, 50 percent of patients whose initial hemorrhagic episode exceeded 500 mL were successfully managed with aggressive use of antepartum transfusions and had a mean prolongation of pregnancy of 17 days [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3543694070">
         <span class="h2">
          Indications for delivery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cesarean birth is indicated for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active labor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A category III fetal heart rate tracing unresponsive to resuscitative measures. (See
         <a class="medical medical_review" href="/z/d/html/16663.html" rel="external">
          "Intrapartum category I, II, and III fetal heart rate tracings: Management", section on 'General approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe and persistent vaginal bleeding such that maternal hemodynamic stability cannot be achieved or maintained.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant vaginal bleeding after 34+0 weeks of gestation – When the clinician believes the volume of vaginal bleeding is significant, we believe the balance of fetal benefit versus maternal risk favors delivery in pregnancies ≥34+0 weeks because the neonatal benefits from avoiding preterm birth decrease with advancing gestational age and the maternal risks from persistent or recurrent bleeding probably increase. However, the exact gestational age threshold and amount of bleeding considered significant are matters of clinician judgment. The decision to deliver these pregnancies is made on a case-by-case basis while observing the patient's course on the labor unit. Delivery should not be delayed to administer antenatal corticosteroids [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3801009507">
         <span class="h2">
          Magnesium sulfate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          Magnesium sulfate
         </a>
         therapy for neuroprotection is a common practice for pregnancies &lt;32 weeks in which the family opts for neonatal interventions and a decision has been made to deliver within 24 hours but not emergently. Emergency delivery because of maternal or fetal status should
         <strong>
          not
         </strong>
         be delayed to administer magnesium sulfate. (See
         <a class="medical medical_review" href="/z/d/html/4481.html" rel="external">
          "Neuroprotective effects of in utero exposure to magnesium sulfate"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For scheduled cesarean births, neuraxial anesthesia is generally the preferred approach. For patients who are actively bleeding or require an emergency cesarean birth, general anesthesia is usually preferred. (See
         <a class="medical medical_review" href="/z/d/html/94367.html" rel="external">
          "Anesthesia for the patient with peripartum hemorrhage", section on 'Placenta previa'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          EXPECTANT MANAGEMENT OF STABLE PATIENTS AFTER A BLEED
         </span>
        </p>
        <p class="headingAnchor" id="H3447876426">
         <span class="h2">
          Candidates and goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         We believe that symptomatic patients &lt;34+0 weeks of gestation who are hemodynamically stable or quickly stabilized and have a normal fetal heart rate pattern are candidates for expectant management. The goal is to prolong pregnancy to enable further fetal growth and maturation, without placing the mother at excessive risk from persistent or recurrent bleeding.
        </p>
        <p>
         Management of placenta previa after acute bleeding is based upon findings from observational studies and clinical experience. A systematic review that attempted to assess the impact of clinical interventions in these pregnancies concluded there were insufficient data upon which to make evidence-based recommendations for clinical practice; only three randomized trials involving a total of 114 participants were identified [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         After the patient has been stabilized, we take the approach described in the following sections.
        </p>
        <p class="headingAnchor" id="H498004976">
         <span class="h2">
          Antenatal corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         A course of antenatal corticosteroid therapy is administered to patients who experience bleeding. Administration can be considered as early as 22+0 to 22+6 weeks of gestation for a patient in whom delivery in the next seven days is anticipated and if the patient is requesting aggressive neonatal intervention. We would give an initial course of steroids to patients whose first bleed is as late as 34+0 to 36+6 weeks of gestation, but the benefits at this gestational age are less clear and use is controversial. Use of antenatal corticosteroids, including rescue (salvage, booster) dosing, is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '34+0 or more weeks'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H620730250">
         <span class="h2">
          Correction of anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral or parenteral iron supplementation may be needed for optimal correction of anemia. Parenteral iron therapy has the advantages of a faster rise in hemoglobin levels and less gastric upset compared with oral therapy. If oral iron is prescribed, stool softeners and a high-fiber diet help to minimize constipation and avoid excess straining that might precipitate bleeding. (See
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy", section on 'Treatment of iron deficiency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3852121216">
         <span class="h2">
          Anti-D immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Theoretically, disruption of the fetomaternal placental interface can result in fetomaternal bleeding. For this reason, guidelines for prevention of RhD alloimmunization suggest administering anti-D-immune globulin to RhD-negative patients who have bleeding from placenta previa [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         Readministration is not necessary if rebleeding occurs within three weeks of administration. If repeated episodes of bleeding occur, the anti-D antibody titer can be checked: a low titer suggests that the anti-D level is sufficient to provide ongoing protection against alloimmunization.
        </p>
        <p>
         Readministration is also not necessary if delivery occurs within three weeks of administration, unless routine postpartum Kleihauer-Betke or flow cytometry detects a large fetomaternal bleed that would not be covered by standard doses of
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         . Use of anti-D immune globulin is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H299425637">
         <span class="h2">
          Fetal assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, active vaginal bleeding is an indication for continuous fetal monitoring. (See
         <a class="local">
          'Maternal and fetal assessment'
         </a>
         above.)
        </p>
        <p>
         There is no proven value of nonstress testing or performing a biophysical profile in a patient with an asymptomatic placenta previa who has no evidence of uteroplacental insufficiency (eg, preeclampsia, fetal growth restriction, oligohydramnios) or another standard indication for antepartum fetal assessment.
        </p>
        <p>
         In pregnancies with coexistent vasa previa, we perform nonstress testing to look for any evidence of cord compression. (See
         <a class="medical medical_review" href="/z/d/html/6807.html" rel="external">
          "Velamentous umbilical cord insertion and vasa previa", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H298124498">
         <span class="h2">
          Autologous blood donation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients may consider autologous blood donation, given the high frequency of bleeding requiring blood transfusion (12 percent in one series [
         <a href="#rid35">
          35
         </a>
         ] and 22 percent in another [
         <a href="#rid36">
          36
         </a>
         ]). However, most pregnant patients, especially those who have bled from a placenta previa, will not meet standard criteria for autologous donation [
         <a href="#rid37">
          37,38
         </a>
         ]. Furthermore, autologous donation is not cost-effective, given the increasing safety of allogeneic blood and the wastage of unused autologous blood. These and other issues related to preoperative autologous blood donation are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7930.html" rel="external">
          "Surgical blood conservation: Preoperative autologous blood donation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3420589591">
         <span class="h2">
          Other interventions
         </span>
        </p>
        <p class="headingAnchor" id="H733826421">
         <span class="h3">
          Tocolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely use tocolytic drugs in the management of placenta previa, given the lack of proven benefits and the known possible harms (see
         <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">
          "Inhibition of acute preterm labor"
         </a>
         ). In patients with contractions, we may use tocolytics (usually
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         ) while administering a course of antenatal corticosteroids if bleeding is diminishing or has ceased and delivery is not otherwise mandated by the maternal or fetal condition. In such patients, uterine contractions may mechanically promote placental separation and bleeding, and thus, tocolysis may reduce or eliminate a potential contributing factor.
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          Indomethacin
         </a>
         is not used due to its inhibitory effect on platelet function and potential adverse fetal/neonatal effects. (See
         <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">
          "Inhibition of acute preterm labor", section on 'Fetal side effects'
         </a>
         .)
        </p>
        <p>
         Some observational studies in patients with symptomatic placenta previa suggest tocolysis may prolong pregnancy and result in an increase in birth weight without causing adverse effects on the mother or fetus [
         <a href="#rid39">
          39,40
         </a>
         ]. However, it is likely that underlying differences in the treated and untreated (control) patients accounted for this benefit. Furthermore, these studies have generally not shown a decrease in the number of episodes of hemorrhage after admission, the total amount of blood loss, or the number of blood transfusions. Other studies have reported that maintenance tocolysis in patients with placenta previa is not beneficial [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1606463091">
         <span class="h3">
          Cerclage
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of high-quality evidence of efficacy and safety, we advise not performing cerclage to improve pregnancy outcome in placenta previa. However, the presence of a stable placenta previa is not a contraindication to cerclage placement when indicated for cervical insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency"
         </a>
         .)
        </p>
        <p>
         Cervical cerclage has been placed in an attempt to minimize early widening of the isthmus, which is thought to promote placental separation [
         <a href="#rid42">
          42
         </a>
         ]. The efficacy of this approach is unproven. Although a meta-analysis of two small randomized trials that evaluated cerclage for improving pregnancy outcome in primarily symptomatic placenta previa [
         <a href="#rid43">
          43,44
         </a>
         ] reported that cervical cerclage reduced the risk of delivery before 34 weeks (relative risk [RR] 0.45, 95% CI 0.23-0.87) and the birth of an infant weighing less than 2000 g (RR 0.34, 95% CI 0.14-0.83), the lack of consistency between trials and methodologic issues prevent making a clear conclusion of benefit [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H716011224">
         <span class="h3">
          Pessary and progesterone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of pessary and
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         showed promising results (less bleeding and preterm birth &lt;34 weeks) in a randomized trial of patients with placenta previa and high risk of preterm birth [
         <a href="#rid45">
          45
         </a>
         ]. A smaller trial using a pessary alone showed promising results but was stopped early due to budgetary issues [
         <a href="#rid46">
          46
         </a>
         ]. More data are needed before we would consider managing patients with this investigational approach.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Inpatient versus outpatient management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with one or two bleeding episodes
         </strong>
         – If the patient's bleeding stops after the first or second bleeding event, we discharge them to home if they meet the criteria described below. (See
         <a class="local">
          'Criteria for discharge'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with three or more bleeding episodes
         </strong>
         – If a third bleeding episode occurs, we generally hospitalize the patient until delivery [
         <a href="#rid30">
          30
         </a>
         ]. Since the frequency and severity of recurrent bleeding episodes are unpredictable, maintaining close proximity to the labor and delivery unit may minimize the risk of serious maternal or fetal complications by enabling prompt access to transfusion therapy and emergency cesarean birth when needed.
        </p>
        <p>
        </p>
        <p>
         One study found that the risk for emergency cesarean birth progressively increased with one, two, and three or more episodes of antepartum bleeding (odds ratio [OR] 7.5, 14, and 27, respectively) and in patients who had had a blood transfusion (OR 6.4) compared with patients with no antepartum bleeding [
         <a href="#rid47">
          47
         </a>
         ]. In this study, 57 percent of patients with bleeding placenta previa had an emergency delivery, and the frequency of emergency delivery was 42 percent after three or more bleeding episodes versus 25 to 30 percent after one or two bleeds.
        </p>
        <p>
         The only randomized trial of outpatient versus inpatient management of patients with placenta previa after resolution of the initial bleeding episode found that outpatient care was not associated with greater morbidity than inpatient management [
         <a href="#rid30">
          30
         </a>
         ]. Patients randomly assigned to the outpatient arm who had a recurrent bleed were treated initially as inpatients and then discharged home after a minimum of 48 to 72 hours if they remained stable with minimal ambulation. Outpatients were instructed to maintain bedrest. However, if these patients had a third episode of bleeding, they were hospitalized until delivery. Significant differences in outcome may not have been appreciated given the small number of participants (53) who participated in this trial.
        </p>
        <p class="headingAnchor" id="H1455367375">
         <span class="h3">
          Criteria for discharge
         </span>
         <span class="headingEndMark">
          —
         </span>
         We discharge selected patients with placenta previa in whom bleeding has stopped for a minimum of 24 hours and who have no other pregnancy complications, although the safety and efficacy of this approach has not been established [
         <a href="#rid30">
          30,48-50
         </a>
         ]. In our practice, candidates for outpatient care should:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Be able to return to the hospital within 20 minutes [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Be reliable (ie, will comply with instructions about sexual activity, etc). (See
         <a class="local">
          'Reducing the risk of bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Be able to maintain modified bed rest at home.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Understand the risks entailed by outpatient management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have an adult companion available 24 hours/day who can immediately transport them to the hospital if there is light bleeding or call an ambulance for severe bleeding.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Management of coexistent PPROM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antepartum decidual hemorrhage is a major risk factor for preterm prelabor rupture of membranes (PPROM), which can occur despite the presence of a complete placenta previa. In these cases, each condition is managed independently. (See
         <a class="medical medical_review" href="/z/d/html/6754.html" rel="external">
          "Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Timing of delivery
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, planned cesarean birth of patients with stable (no bleeding or minimal bleeding) placenta previa should be accomplished at 36+0 to 37+6 weeks. (See
         <a class="local">
          'Timing of delivery'
         </a>
         above.)
        </p>
        <p>
         Expectant management is terminated, and emergency cesarean birth is indicated if any of the following occur:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Labor
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any vaginal bleeding with a category III fetal heart rate tracing unresponsive to resuscitative measures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe and persistent vaginal bleeding such that maternal hemodynamic stability cannot be achieved or maintained
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant vaginal bleeding at ≥34+0 weeks of gestation (see
         <a class="local">
          'Indications for delivery'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          CESAREAN BIRTH
         </span>
         <span class="headingEndMark">
          —
         </span>
         A cesarean birth is always indicated when there is sonographic evidence of placenta previa and the fetus has a reasonable chance of extrauterine survival. As long as the mother remains hemodynamically stable, vaginal birth may be considered in rare circumstances, such as in the presence of a fetal demise or fetus without a reasonable chance of extrauterine survival.
        </p>
        <p class="headingAnchor" id="H2061671215">
         <span class="h2">
          Preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Planning for the possibility of postpartum hemorrhage is critical for reducing morbidity. (See
         <a class="medical medical_review" href="/z/d/html/6710.html" rel="external">
          "Overview of postpartum hemorrhage", section on 'Institutional planning and preparation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6710.html" rel="external">
          "Overview of postpartum hemorrhage", section on 'Early recognition, assessment, and intervention'
         </a>
         .)
        </p>
        <p>
         Two to four units of packed red blood cells should be available for the cesarean birth. Appropriate surgical expertise and instruments for performance of a cesarean hysterectomy should also be available since these patients are at increased risk of placenta accreta spectrum, even in the absence of a prior cesarean birth. Evaluation for placenta previa-accreta spectrum should have been performed antenatally, with appropriate preparations for management, if present. (See
         <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">
          "Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">
          "Placenta accreta spectrum: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5395.html" rel="external">
          "Peripartum hysterectomy for management of hemorrhage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality", section on 'Placenta previa-accreta spectrum'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H540252620">
         <span class="h2">
          Management of the placenta
         </span>
         <span class="headingEndMark">
          —
         </span>
         The surgeon should try to avoid disrupting the placenta when entering the uterus. If the placenta is incised, hemorrhage from fetal vessels can result in significant neonatal anemia; therefore, the fetus should be delivered rapidly, and the cord promptly clamped.
        </p>
        <p>
         Preoperative or intraoperative sonographic placental localization is helpful in determining the position for the hysterotomy incision. For intraoperative imaging, the transducer is placed in a sterile plastic bag and sleeve, and sterile gel is applied to the uterine serosa; the best incision site for avoiding the placenta can then be mapped sonographically.
        </p>
        <p>
         If the placenta is in an anterolateral location, a vertical incision can be made in the lower uterine segment on the opposite anterolateral side from the placenta. If the placenta wraps around the cervix from the anterior to posterior lower uterine segment in the midline, a transverse or vertical incision above it may be possible [
         <a href="#rid52">
          52,53
         </a>
         ], although a vertical incision often results in extension into the upper uterine segment. Anterior previas are associated with a larger volume of bleeding at cesarean than posterior previas [
         <a href="#rid54">
          54-57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1571129265">
         <span class="h2">
          Management of postpartum hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         is given routinely to reduce the risk of postpartum hemorrhage. The addition of second uterotonic drug or
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         can be considered as well (see
         <a class="medical medical_review" href="/z/d/html/4437.html" rel="external">
          "Management of the third stage of labor: Prophylactic pharmacotherapy to minimize hemorrhage", section on 'Active management'
         </a>
         ). Nevertheless, severe bleeding may occur from the placental bed after placental expulsion: in a systematic review, 16 to 29 percent of patients with a placenta previa had a postpartum hemorrhage [
         <a href="#rid58">
          58
         </a>
         ]. The reason for the increased risk of postpartum hemorrhage is thought to be that the myometrium of the lower uterine segment does not contract as effectively as the upper uterine segment, and thus may impede physiologic hemostasis from a lower segment placental bed. In some cases, hemorrhage is due to focal placenta accreta. Even in the absence of the accreta spectrum, patients with a previous cesarean may lack sufficient lower uterine segment contractility in the area of the scar to stop bleeding.
        </p>
        <p>
         Postpartum hemorrhage is approached in the following ways.
        </p>
        <p class="headingAnchor" id="H2225639017">
         <span class="h3">
          Step one: Administer uterotonic drugs and tranexamic acid; consider temporizing maneuvers
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacotherapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         is administered and titrated, as needed, to control heavy bleeding. If oxytocin alone does not rapidly control hemorrhage, we administer
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         concomitantly with additional uterotonic drugs (
         <a class="drug drug_general" data-topicid="9203" href="/z/d/drug information/9203.html" rel="external">
          carboprost tromethamine
         </a>
         [prostaglandin F
         <sub>
          2
         </sub>
         alpha] or
         <a class="drug drug_general" data-topicid="9637" href="/z/d/drug information/9637.html" rel="external">
          methylergonovine
         </a>
         ). Some providers administer tranexamic acid prophylactically rather than therapeutically. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer tranexamic acid'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Manage atony'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4437.html" rel="external">
          "Management of the third stage of labor: Prophylactic pharmacotherapy to minimize hemorrhage", section on 'Tranexamic acid'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tourniquets
         </strong>
         – Tourniquets may be useful as a temporizing measure while pharmacotherapy is administered and taking effect or while surgical interventions are being considered [
         <a href="#rid59">
          59,60
         </a>
         ]. A bladder catheter or Penrose drain is tied tightly around the uterus as low as possible to occlude the uterine vessels in the broad ligaments and then secured with a clamp  (
         <a class="graphic graphic_figure graphicRef113917" href="/z/d/graphic/113917.html" rel="external">
          figure 1
         </a>
         ). A second or third tourniquet can also be applied, as needed. (See
         <a class="medical medical_review" href="/z/d/html/15798.html" rel="external">
          "Techniques to reduce blood loss during abdominal or laparoscopic myomectomy", section on 'Tourniquets'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H736904558">
         <span class="h3">
          Step two: Treat focal bleeding, if present
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following options may control bleeding from a small focal area:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemostatic square sutures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placement of fibrin glue or patch over area of oozing to promote clotting [
         <a href="#rid61">
          61
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Application of
         <a class="drug drug_general" data-topicid="83319" href="/z/d/drug information/83319.html" rel="external">
          ferric subsulfate
         </a>
         (Monsel's solution) to oozing area
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placental site injection of
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excision, if the area is small and easily accessible, particularly in cases of focal placenta accreta with persistent bleeding
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3136350442">
         <span class="h4">
          Hemostatic square sutures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ligation of myometrial vessels at the placental site will control focal bleeding in patients who have a focal placenta accreta and some patients who responded poorly to intravenous uterotonic therapy.
        </p>
        <p>
         The Affronti endouterine hemostatic square suture technique involves making four to six 2 by 2 cm squares in the area of placental bed bleeding [
         <a href="#rid62">
          62
         </a>
         ]. The 1.0 polyglactin 910 sutures should penetrate the decidua and extend into the myometrium but not beyond the uterine serosa  (
         <a class="graphic graphic_figure graphicRef113950" href="/z/d/graphic/113950.html" rel="external">
          figure 2
         </a>
         ). The ends of the sutures are tied down tightly to compress the enclosed vessels.
        </p>
        <p>
         In one study, multiple square sutures stopped postpartum hemorrhage in 28 of 30 cases (93 percent) [
         <a href="#rid63">
          63
         </a>
         ]. Twenty patients subsequently underwent hysteroscopy: eight (40 percent) had no intrauterine adhesions, nine (45 percent) had thin adhesions that were removed easily by the tip of the hysteroscope, two (10 percent) had moderate intrauterine adhesions that were resected, and one (10 percent) had severe intrauterine adhesions.
        </p>
        <p class="headingAnchor" id="H2867479360">
         <span class="h4">
          Placental site injection of vasopressin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The authors have not used this technique in patients with placenta previa. Placental site injection of
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         to reduce bleeding, while biologically plausible and potentially clinically relevant, is based on two small case series. After removal of the placenta, subendometrial injection of vasopressin at the placental implantation site may reduce bleeding [
         <a href="#rid64">
          64,65
         </a>
         ]. The favorable effect has been attributed to binding to the vasopressin V1α receptor, which is highly expressed in smooth muscle cells in the lower segment of the uterus. Intravascular injection should be avoided, as it can cause severe adverse cardiovascular effects (bradycardia, cardiac arrhythmia, ischemia, right heart failure, shock, cardiac arrest, limb ischemia).
        </p>
        <p>
         In one study, local injection of 4 units of
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         in 20 mL of
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         into the placental implantation site significantly reduced blood loss without increasing morbidity (blood loss: with vasopressin 1149 mL, without vasopressin 1634 mL) [
         <a href="#rid65">
          65
         </a>
         ]. In a case report, 5 units of vasopressin in 20 mL saline injected in 1 to 2 mL amounts into the area of placental implantation stopped bleeding within 90 seconds [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2093821352">
         <span class="h3">
          Step three: Ligation of the uterine and utero-ovarian arteries (O'Leary stitch)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ligation of the uterine and utero-ovarian arteries (O'Leary stitch) can decrease diffuse uterine bleeding by reducing perfusion pressure in the myometrium. The technique, which can be applied rapidly, is described separately. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Laceration of the uterine artery or utero-ovarian artery branches'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H833426454">
         <span class="h3">
          Step four: Intrauterine balloon tamponade and/or uterine compression sutures
         </span>
         <span class="headingEndMark">
          —
         </span>
         If bleeding persists, the next step is either intrauterine balloon tamponade or placement of uterine compression sutures. As no trials have compared the two approaches directly in this setting, the choice depends on the clinical judgment/preference of the surgeon.
        </p>
        <p>
         Uterine compression sutures may be more effective for atony and fundal bleeding, whereas the balloon may be more effective for lower segment bleeding. However, an advantage of placing the balloon first is that it is a quick and easy procedure and if it does not work, the balloon can be deflated, compression sutures can be placed, and then the balloon can be reinflated, if needed. If the compression sutures are placed first, then they will have to be removed in order to place a balloon.
        </p>
        <p class="headingAnchor" id="H3314819015">
         <span class="h4">
          Intrauterine balloon tamponade
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intrauterine balloon tamponade is a fast and often effective procedure for control of hemorrhage in patients who have not responded to drug therapy or focal placental site suture ligation. A meta-analysis found that, after placement of an intrauterine balloon, 87 percent of patients with previa had arrest of bleeding without maternal death and additional surgical or radiologic interventions [
         <a href="#rid66">
          66
         </a>
         ]. In a small trial in which 13 patients with intractable bleeding from placenta previa were randomly assigned to insertion of a balloon or hemostatic square sutures, the balloon group had greater reductions in operative time and intraoperative blood loss (time: 63 versus 78 minutes; intraoperative blood loss: 1520 versus 1946 mL) [
         <a href="#rid67">
          67
         </a>
         ]. Routine prophylactic use of a balloon has also been shown to be effective in controlling blood loss during and after cesarean birth in patients with placenta previa [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         The stem of a balloon catheter can be passes through the uterine incision, through the cervical os, and then into the vagina; an assistant then pulls the end of the catheter out of the introitus. If it is difficult to pass the catheter through the cervical os, an assistant can pass the tip of a small forceps from the vagina through the cervical os to the uterine incision [
         <a href="#rid69">
          69
         </a>
         ]. The surgeon then places the stem of the catheter into the open tip so the assistant can pull it into the vagina while the surgeon places the balloon end in an appropriate place within the uterine cavity. The balloon can be left deflated or inflated with 50 to 100 mL sterile
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to reduce the risk of puncture when the hysterotomy incision is closed. After the uterine incision is closed, the assistant inflates the balloon to its maximum volume with sterile fluid  (
         <a class="graphic graphic_table graphicRef128495" href="/z/d/graphic/128495.html" rel="external">
          table 3
         </a>
         ) while the surgeon inspects the uterus from above. (See
         <a class="medical medical_review" href="/z/d/html/4440.html" rel="external">
          "Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device"
         </a>
         .)
        </p>
        <p>
         An intrauterine vacuum-induced hemorrhage-control device has been used to manage postpartum hemorrhage caused by atony, with minimal experience in patients with bleeding related to abnormal placentation. (See
         <a class="medical medical_review" href="/z/d/html/4440.html" rel="external">
          "Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device", section on 'Intrauterine vacuum'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1285853240">
         <span class="h4">
          Uterine compression sutures
         </span>
         <span class="headingEndMark">
          —
         </span>
         If balloon tamponade is ineffective, the balloon can be deflated and a B-Lynch uterine compression suture is applied  (
         <a class="graphic graphic_figure graphicRef71907" href="/z/d/graphic/71907.html" rel="external">
          figure 3
         </a>
         ). The hysterotomy site is then closed, the uterus replaced in the pelvis (if previously exteriorized), and the balloon is reinflated, thereby applying pressure to both the outer and inner surfaces of the myometrium. [
         <a href="#rid69">
          69,70
         </a>
         ]. It is important to observe the myometrium and stop instilling fluid before undue blanching occurs at the compression suture sites, which might lead to rupture or uterine necrosis. It is also important to observe for vaginal bleeding to see if hemorrhage has been controlled. (See
         <a class="medical medical_review" href="/z/d/html/4440.html" rel="external">
          "Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4269948672">
         <span class="h3">
          Refractory patients
         </span>
        </p>
        <p class="headingAnchor" id="H1723399452">
         <span class="h4">
          Consider arterial embolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the above measures have failed, uterine or hypogastric artery embolization in an operating room with the full surgical team in attendance is an option if the facility has a hybrid operating room, or an operating room that allows simultaneous surgery and embolization (an appropriately sensitive portable C-arm and carbon fiber table). We believe embolization is preferable to surgical internal iliac artery ligation. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Consider uterine or hypogastric artery embolization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2021499709">
         <span class="h4">
          Hysterectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hysterectomy is a definitive treatment of uterine bleeding when fertility preserving procedures have not reduced the bleeding to a manageable level. Ideally, it should be performed before severe hypovolemia, tissue hypoxia, hypothermia, electrolyte abnormalities, and acidosis have developed, which further compromise the patient's status. (See
         <a class="medical medical_review" href="/z/d/html/5395.html" rel="external">
          "Peripartum hysterectomy for management of hemorrhage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2282209880">
         <span class="h1">
          DELIVERY OF PATIENTS WITH A LOW-LYING PLACENTA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal route for delivery of pregnancies where the distance between the placental edge and internal os is 0 to 20 mm is debatable. In these cases, the fetal head may tamponade the adjacent placenta, thus preventing hemorrhage.
        </p>
        <p>
         Although a variety of factors influence the decision to perform cesarean birth, the following data from a meta-analysis support allowing a trial of labor in pregnancies in which the placenta is more than 10 mm from the internal os. If this distance is ≤10 mm, these pregnancies are at high risk of intrapartum hemorrhage necessitating emergency cesarean birth; therefore, we suggest scheduled cesarean birth at 39 weeks to minimize this risk. However, this is a shared decision, and some patients may choose to undertake a trial of labor since a substantial proportion will be able to successfully deliver vaginally. If a trial of labor with a low-lying placenta is attempted, the facility should have the ability to perform an emergency cesarean birth.
        </p>
        <p>
         A systematic review of 10 studies of nearly 600 patients with a low-lying placenta undergoing a trial of labor reported outcomes by the distance between the placental edge to the internal os [
         <a href="#rid71">
          71
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         0 to 10 mm – vaginal delivery: 43 percent (95% CI 28-59), emergency cesarean: 45 percent (95% CI 22–69)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         11 to 20 mm – vaginal delivery: 85 percent (95% CI 70-96), emergency cesarean: 14 percent (95% CI 4.2–29)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         &gt;20 mm – vaginal delivery: 82 percent (95% CI 58-97), emergency cesarean: 10 percent (95% CI 2.2–22.3)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There was no difference in blood transfusion or postpartum hemorrhage among groups.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          PREGNANCY TERMINATION IN WOMEN WITH PLACENTA PREVIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of a placenta previa does not preclude second-trimester pregnancy termination by standard techniques, although data are limited to a few studies [
         <a href="#rid72">
          72-77
         </a>
         ]. The approach to termination in this clinical setting is described separately. (See
         <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">
          "Overview of second-trimester pregnancy termination", section on 'Placental abnormalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1615854919">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118733.html" rel="external">
          "Society guideline links: Obstetric hemorrhage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31754726">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83440.html" rel="external">
          "Patient education: Placenta previa (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Digital cervical examination should be avoided
         </strong>
         . It can result in severe hemorrhage. (See
         <a class="local">
          'Reducing the risk of bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute management of bleeding previa
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An actively bleeding placenta previa is a potential obstetric emergency. Patients with active bleeding are hospitalized for close maternal and fetal monitoring, including (see
         <a class="local">
          'Maternal and fetal assessment'
         </a>
         above and
         <a class="local">
          'Laboratory testing and notifying the blood bank'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Monitoring maternal blood loss and hemodynamic status.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Obtaining a complete blood count and sending blood for type and antibody screen or cross-match, depending on the likelihood of transfusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Evaluating the fibrinogen level, activated partial thromboplastin time, and prothrombin time in patients suspected of coexistent abruption or with heavy blood loss resulting in hemodynamic instability.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Monitoring the fetal heart rate
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Not getting behind in replacement of blood products is essential. Acute hemorrhage may not be associated with an immediate reduction in either blood pressure or hematocrit in an otherwise healthy young patient  (
         <a class="graphic graphic_table graphicRef56885" href="/z/d/graphic/56885.html" rel="external">
          table 1
         </a>
         ). Thus, we have a low threshold for transfusing symptomatic patients. (See
         <a class="local">
          'Transfusion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Initially, we transfuse two to four units of typed and crossed packed RBCs, without fresh frozen plasma or platelets as long as the fibrinogen level is &gt;250 mg/dL and the platelet count is &gt;100,000/microL. Our goal is a final hemoglobin value &gt;10 g/dL.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If the patient continues to bleed, we use the same blood product transfusion ratios as for patients with severe hemorrhage of other etiologies: a 1:1:1 ratio of packed RBC:fresh frozen plasma:platelets. If available, thromboelastography (TEG) or rotational thromboelastometry (ROTEM)-based transfusion algorithms can be helpful.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If the patient fails to stabilize, we initiate a massive transfusion protocol  (
         <a class="graphic graphic_algorithm graphicRef91236" href="/z/d/graphic/91236.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most patients who initially present with symptomatic placenta previa respond to supportive therapy. Indications for emergency cesarean birth include active labor, refractory life-threatening maternal hemorrhage, a category III fetal heart rate tracing, and significant vaginal bleeding at ≥34+0 weeks of gestation. (See
         <a class="local">
          'Acute care of bleeding patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Expectant management after an acute bleed
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         After a bleeding episode has resolved, outpatient management of select patients is reasonable. We counsel these patients to avoid excess physical activity, including sexual intercourse, and to call their provider promptly if bleeding or labor occurs. They should be able to return to the hospital quickly if rebleeding occurs and should not have additional pregnancy complications. (See
         <a class="local">
          'Expectant management of stable patients after a bleed'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A course of antenatal corticosteroid therapy is administered.
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          Anti-D immune globulin
         </a>
         is administered to RhD-negative patients. (See
         <a class="local">
          'Antenatal corticosteroids'
         </a>
         above and
         <a class="local">
          'Anti-D immune globulin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We schedule cesarean birth at 36+0 to 37+6 weeks (see
         <a class="local">
          'Timing of delivery'
         </a>
         above). Incision of the placenta should be avoided, as this increases the risk of fetal hemorrhage. (See
         <a class="local">
          'Cesarean birth'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic previa
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The main goals during management of asymptomatic patients with placenta previa are to:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Determine whether the previa resolves with increasing gestational age. Follow-up transvaginal ultrasonography is performed at 32 weeks of gestation. If the placenta is morbidly adherent (placenta accreta spectrum), cesarean birth is planned for 34+0 to 35+6 weeks of gestation. If the placenta is over or &lt;2 cm from the internal os but not morbidly adherent, transvaginal ultrasound is repeated at 36 weeks  (
         <a class="graphic graphic_algorithm graphicRef115747" href="/z/d/graphic/115747.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Monitoring placental position'
         </a>
         above and
         <a class="local">
          'Excluding placenta accreta spectrum'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Counsel the patient on measures to reduce the risk of bleeding. (See
         <a class="local">
          'Reducing the risk of bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cesarean birth is performed at 36+0 to 37+6 weeks of gestation. (See
         <a class="local">
          'Timing of delivery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest a course of antenatal corticosteroids 48 hours before a cesarean birth scheduled before 37+0 weeks of gestation, if not previously given (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Antenatal corticosteroids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cesarean birth
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Planning for the possibility of postpartum hemorrhage, which occurs in up to an approximate 30 percent of cases, is critical for reducing morbidity. Disruption of the placenta at hysterotomy should be avoided, if possible. (See
         <a class="local">
          'Preparation'
         </a>
         above and
         <a class="local">
          'Management of the placenta'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The management of postpartum hemorrhage involves a stepwise approach, initially with uterotonic drugs and
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         , followed by standard surgical interventions (eg, suturing focal bleeding, ligation of the uterine and utero-ovarian arteries [O'Leary stitch], placement of uterine compression sutures and/or intrauterine balloon tamponade), and ultimately arterial embolization or hysterectomy. Uterine tourniquets may be useful as a temporizing measure while pharmacotherapy is administered and taking effect or while surgical interventions are being considered  (
         <a class="graphic graphic_figure graphicRef113917" href="/z/d/graphic/113917.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Management of postpartum hemorrhage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-lying placenta
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A low-lying placenta is one in which the distance between the placental edge and internal cervical os is 0 to 20 mm. For women with a low-lying placenta where the placental edge is 0 to 10 mm from the edge of the internal os, we suggest planned cesarean birth (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). These pregnancies are at high (&gt;50 percent) risk for intrapartum hemorrhage necessitating emergency cesarean delivery. We suggest a trial of labor for those with placental edge to internal os distance 11 to 20 mm (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). These patients have a &gt;80 percent chance of successful vaginal birth. However, these are shared decisions between clinician and patient. (See
         <a class="local">
          'Delivery of patients with a low-lying placenta'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Reddy UM, Abuhamad AZ, Levine D, et al. Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging workshop. Obstet Gynecol 2014; 123:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer KT, Bonzini M, Harris EC, et al. Work activities and risk of prematurity, low birth weight and pre-eclampsia: an updated review with meta-analysis. Occup Environ Med 2013; 70:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam CM, Wong SF, Chow KM, Ho LC. Women with placenta praevia and antepartum haemorrhage have a worse outcome than those who do not bleed before delivery. J Obstet Gynaecol 2000; 20:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Love CD, Fernando KJ, Sargent L, Hughes RG. Major placenta praevia should not preclude out-patient management. Eur J Obstet Gynecol Reprod Biol 2004; 117:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen DM, Peek MJ. Do women with placenta praevia without antepartum haemorrhage require hospitalization? Aust N Z J Obstet Gynaecol 1994; 34:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ononeze BO, Ononeze VN, Holohan M. Management of women with major placenta praevia without haemorrhage: a questionnaire-based survey of Irish obstetricians. J Obstet Gynaecol 2006; 26:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin JE, Shin JC, Lee Y, Kim SJ. Serial Change in Cervical Length for the Prediction of Emergency Cesarean Section in Placenta Previa. PLoS One 2016; 11:e0149036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stafford IA, Dashe JS, Shivvers SA, et al. Ultrasonographic cervical length and risk of hemorrhage in pregnancies with placenta previa. Obstet Gynecol 2010; 116:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghi T, Youssef A. Ultrasonographic cervical length and risk of hemorrhage in pregnancies with placenta previa. Obstet Gynecol 2010; 116:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Maternal-Fetal Medicine (SMFM). Electronic address:
           <span class="__cf_email__" data-cfemail="8cfcf9eeffccffe1eae1a2e3feeb">
            [email protected]
           </span>
           , Gyamfi-Bannerman C. Society for Maternal-Fetal Medicine (SMFM) Consult Series #44: Management of bleeding in the late preterm period. Am J Obstet Gynecol 2018; 218:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831. Obstet Gynecol 2021; 138:e35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Kadri HM, Al Anazi BK, Tamim HM. Visual estimation versus gravimetric measurement of postpartum blood loss: a prospective cohort study. Arch Gynecol Obstet 2011; 283:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoong W, Karavolos S, Damodaram M, et al. Observer accuracy and reproducibility of visual estimation of blood loss in obstetrics: how accurate and consistent are health-care professionals? Arch Gynecol Obstet 2010; 281:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bose P, Regan F, Paterson-Brown S. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. BJOG 2006; 113:919.
          </a>
         </li>
         <li class="breakAll">
          Lyndon A, Miller S, Huwe V, Rosen M, et al. Blood loss: Clinical techniques for ongoing quantitative measurement. California Maternal Quality Care Collaborative. CMQCC Obstetric Hemorrhage Toolkit; 1/6/2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz V, Abalos E, Carroli G. Methods for blood loss estimation after vaginal birth. Cochrane Database Syst Rev 2018; 9:CD010980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schorn MN. Measurement of blood loss: review of the literature. J Midwifery Womens Health 2010; 55:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang WH, Deneux-Tharaux C, Brocklehurst P, et al. Effect of a collector bag for measurement of postpartum blood loss after vaginal delivery: cluster randomised trial in 13 European countries. BMJ 2010; 340:c293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Main EK, Goffman D, Scavone BM, et al. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Hemorrhage. Obstet Gynecol 2015; 126:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodnough LT, Daniels K, Wong AE, et al. How we treat: transfusion medicine support of obstetric services. Transfusion 2011; 51:2540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacheco LD, Hankins GDV, Saad AF, et al. Tranexamic Acid for the Management of Obstetric Hemorrhage. Obstet Gynecol 2017; 130:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Martin HB, Morris JL. Anti-shock garment in postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol 2008; 22:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Ojengbede O, Turan JM, et al. A comparative study of the non-pneumatic anti-shock garment for the treatment of obstetric hemorrhage in Nigeria. Int J Gynaecol Obstet 2009; 107:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Fathalla MM, Youssif MM, et al. A comparative study of the non-pneumatic anti-shock garment for the treatment of obstetric hemorrhage in Egypt. Int J Gynaecol Obstet 2010; 109:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lester F, Stenson A, Meyer C, et al. Impact of the Non-pneumatic Antishock Garment on pelvic blood flow in healthy postpartum women. Am J Obstet Gynecol 2011; 204:409.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cotton DB, Read JA, Paul RH, Quilligan EJ. The conservative aggressive management of placenta previa. Am J Obstet Gynecol 1980; 137:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silver R, Depp R, Sabbagha RE, et al. Placenta previa: aggressive expectant management. Am J Obstet Gynecol 1984; 150:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farine D, Peisner DB, Timor-Tritsch IE. Placenta previa--is the traditional diagnostic approach satisfactory? J Clin Ultrasound 1990; 18:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wing DA, Paul RH, Millar LK. Management of the symptomatic placenta previa: a randomized, controlled trial of inpatient versus outpatient expectant management. Am J Obstet Gynecol 1996; 175:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Obstetric Practice. ACOG committee opinion. Placenta accreta. Number 266, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neilson JP. Interventions for suspected placenta praevia. Cochrane Database Syst Rev 2003; :CD001998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fung Kee Fung K, Eason E, Crane J, et al. Prevention of Rh alloimmunization. J Obstet Gynaecol Can 2003; 25:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 1999; 66:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olive EC, Roberts CL, Algert CS, Morris JM. Placenta praevia: maternal morbidity and place of birth. Aust N Z J Obstet Gynaecol 2005; 45:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg T, Pariente G, Sergienko R, et al. Critical analysis of risk factors and outcome of placenta previa. Arch Gynecol Obstet 2011; 284:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinsmoor MJ, Hogg BB. Autologous blood donation with placenta previa: is it feasible? Am J Perinatol 1995; 12:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toedt ME. Feasibility of autologous blood donation in patients with placenta previa. J Fam Pract 1999; 48:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besinger RE, Moniak CW, Paskiewicz LS, et al. The effect of tocolytic use in the management of symptomatic placenta previa. Am J Obstet Gynecol 1995; 172:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma A, Suri V, Gupta I. Tocolytic therapy in conservative management of symptomatic placenta previa. Int J Gynaecol Obstet 2004; 84:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verspyck E, de Vienne C, Muszynski C, et al. Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial. PLoS One 2017; 12:e0173717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goto M, Hasegawa J, Arakaki T, et al. Placenta previa with early opening of the uterine isthmus is associated with high risk of bleeding during pregnancy, and massive haemorrhage during caesarean delivery. Eur J Obstet Gynecol Reprod Biol 2016; 201:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arias F. Cervical cerclage for the temporary treatment of patients with placenta previa. Obstet Gynecol 1988; 71:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cobo E, Conde-Agudelo A, Delgado J, et al. Cervical cerclage: an alternative for the management of placenta previa? Am J Obstet Gynecol 1998; 179:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barinov SV, Shamina IV, Di Renzo GC, et al. The role of cervical pessary and progesterone therapy in the phenomenon of placenta previa migration. J Matern Fetal Neonatal Med 2020; 33:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stafford IA, Garite TJ, Maurel K, et al. Cervical Pessary versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women with Placenta Previa: A Randomized Controlled Trial. AJP Rep 2019; 9:e160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiter L, Eschbach SJ, Burgers M, et al. Predictors for Emergency Cesarean Delivery in Women with Placenta Previa. Am J Perinatol 2016; 33:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mouer JR. Placenta previa: antepartum conservative management, inpatient versus outpatient. Am J Obstet Gynecol 1994; 170:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Droste S, Keil K. Expectant management of placenta previa: cost-benefit analysis of outpatient treatment. Am J Obstet Gynecol 1994; 170:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angelo LJ, Irwin LF. Conservative management of placenta previa: a cost-benefit analysis. Am J Obstet Gynecol 1984; 149:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravelli AC, Jager KJ, de Groot MH, et al. Travel time from home to hospital and adverse perinatal outcomes in women at term in the Netherlands. BJOG 2011; 118:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kayem G, Davy C, Goffinet F, et al. Conservative versus extirpative management in cases of placenta accreta. Obstet Gynecol 2004; 104:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotsuji F, Nishijima K, Kurokawa T, et al. Transverse uterine fundal incision for placenta praevia with accreta, involving the entire anterior uterine wall: a case series. BJOG 2013; 120:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jing L, Wei G, Mengfan S, Yanyan H. Effect of site of placentation on pregnancy outcomes in patients with placenta previa. PLoS One 2018; 13:e0200252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young BC, Nadel A, Kaimal A. Does previa location matter? Surgical morbidity associated with location of a placenta previa. J Perinatol 2014; 34:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baba Y, Matsubara S, Ohkuchi A, et al. Anterior placentation as a risk factor for massive hemorrhage during cesarean section in patients with placenta previa. J Obstet Gynaecol Res 2014; 40:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang DG, We JS, Shin JU, et al. Maternal outcomes according to placental position in placental previa. Int J Med Sci 2011; 8:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan D, Xia Q, Liu L, et al. The Incidence of Postpartum Hemorrhage in Pregnant Women with Placenta Previa: A Systematic Review and Meta-Analysis. PLoS One 2017; 12:e0170194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breen M. Temporary treatment of severe postpartum hemorrhage. Int J Gynaecol Obstet 2012; 118:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng L, Chang Q, Wang Y, et al. Tourniquet device for hemorrhage control during cesarean section of complete placenta previa pregnancies. J Obstet Gynaecol Res 2014; 40:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg JA, Robinson JN, Carabuena JM, et al. Use of a Fibrin Sealant Patch at Cesarean for Conservative Management of Morbidly Adherent Placenta. AJP Rep 2018; 8:e325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arduini M, Epicoco G, Clerici G, et al. B-Lynch suture, intrauterine balloon, and endouterine hemostatic suture for the management of postpartum hemorrhage due to placenta previa accreta. Int J Gynaecol Obstet 2010; 108:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alouini S, Coly S, Mégier P, et al. Multiple square sutures for postpartum hemorrhage: results and hysteroscopic assessment. Am J Obstet Gynecol 2011; 205:335.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaki ZM, Bahar AM. Massive haemorrhage due to placenta praevia accreta: a useful role for vasopressin. J Obstet Gynaecol 1997; 17:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato S, Tanabe A, Kanki K, et al. Local injection of vasopressin reduces the blood loss during cesarean section in placenta previa. J Obstet Gynaecol Res 2014; 40:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez S, Conde-Agudelo A, Borovac-Pinheiro A, et al. Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis. Am J Obstet Gynecol 2020; 222:293.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavak SB, Atilgan R, Demirel I, et al. Endouterine hemostatic square suture vs. Bakri balloon tamponade for intractable hemorrhage due to complete placenta previa. J Perinat Med 2013; 41:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arakaki T, Matsuoka R, Takita H, et al. The routine use of prophylactic Bakri balloon tamponade contributes to blood loss control in major placenta previa. Int J Gynaecol Obstet 2021; 154:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsubara S, Kuwata T, Baba Y, et al. A novel 'uterine sandwich' for haemorrhage at caesarean section for placenta praevia. Aust N Z J Obstet Gynaecol 2014; 54:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoong W, Ridout A, Memtsa M, et al. Application of uterine compression suture in association with intrauterine balloon tamponade ('uterine sandwich') for postpartum hemorrhage. Acta Obstet Gynecol Scand 2012; 91:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen C, de Mooij YM, Blomaard CM, et al. Vaginal delivery in women with a low-lying placenta: a systematic review and meta-analysis. BJOG 2019; 126:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas AG, Alvarez M, Friedman F Jr, et al. The effect of placenta previa on blood loss in second-trimester pregnancy termination. Obstet Gynecol 1994; 84:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halperin R, Vaknin Z, Langer R, et al. Late midtrimester pregnancy termination in the presence of placenta previa. J Reprod Med 2003; 48:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruano R, Dumez Y, Cabrol D, Dommergues M. Second- and third-trimester therapeutic terminations of pregnancy in cases with complete placenta previa--does feticide decrease postdelivery maternal hemorrhage? Fetal Diagn Ther 2004; 19:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakayama D, Masuzaki H, Miura K, et al. Effect of placenta previa on blood loss in second-trimester abortion by labor induction using gemeprost. Contraception 2007; 75:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pei R, Wang G, Wang H, et al. Efficacy and Safety of Prophylactic Uterine Artery Embolization in Pregnancy Termination with Placenta Previa. Cardiovasc Intervent Radiol 2017; 40:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang N, Li XM, Fei YL, et al. Effects of prophylactic uterine artery embolization on second-trimester induced abortions in patients with placenta previa. Int J Gynaecol Obstet 2018; 143:205.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6809 Version 59.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24785860" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23343859" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Work activities and risk of prematurity, low birth weight and pre-eclampsia: an updated review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15512459" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Women with placenta praevia and antepartum haemorrhage have a worse outcome than those who do not bleed before delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15474239" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Major placenta praevia should not preclude out-patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7980298" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Do women with placenta praevia without antepartum haemorrhage require hospitalization?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17071425" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Management of women with major placenta praevia without haemorrhage: a questionnaire-based survey of Irish obstetricians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26863133" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Serial Change in Cervical Length for the Prediction of Emergency Cesarean Section in Placenta Previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733440" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ultrasonographic cervical length and risk of hemorrhage in pregnancies with placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21099628" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Ultrasonographic cervical length and risk of hemorrhage in pregnancies with placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29079144" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Society for Maternal-Fetal Medicine (SMFM) Consult Series #44: Management of bleeding in the late preterm period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34259491" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20508942" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Visual estimation versus gravimetric measurement of postpartum blood loss: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19434419" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Observer accuracy and reproducibility of visual estimation of blood loss in obstetrics: how accurate and consistent are health-care professionals?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16907938" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16907938" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30211952" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Methods for blood loss estimation after vaginal birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20129226" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Measurement of blood loss: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20123835" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of a collector bag for measurement of postpartum blood loss after vaginal delivery: cluster randomised trial in 13 European countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26241269" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : National Partnership for Maternal Safety: Consensus Bundle on Obstetric Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21542850" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : How we treat: transfusion medicine support of obstetric services.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17413923" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885402" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Tranexamic Acid for the Management of Obstetric Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18805742" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Anti-shock garment in postpartum haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19628207" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A comparative study of the non-pneumatic anti-shock garment for the treatment of obstetric hemorrhage in Nigeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20096836" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A comparative study of the non-pneumatic anti-shock garment for the treatment of obstetric hemorrhage in Egypt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21439543" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Impact of the Non-pneumatic Antishock Garment on pelvic blood flow in healthy postpartum women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7395932" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The conservative aggressive management of placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6476023" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Placenta previa: aggressive expectant management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2161001" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Placenta previa--is the traditional diagnostic approach satisfactory?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8885726" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Management of the symptomatic placenta previa: a randomized, controlled trial of inpatient versus outpatient expectant management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12053897" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : ACOG committee opinion. Placenta accreta. Number 266, January 2002. American College of Obstetricians and Gynecologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12804418" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Interventions for suspected placenta praevia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970812" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prevention of Rh alloimmunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10458556" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16401216" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Placenta praevia: maternal morbidity and place of birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20652281" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Critical analysis of risk factors and outcome of placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8579645" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Autologous blood donation with placenta previa: is it feasible?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10086766" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Feasibility of autologous blood donation in patients with placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7778631" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The effect of tocolytic use in the management of symptomatic placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871511" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tocolytic therapy in conservative management of symptomatic placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28333939" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27039247" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Placenta previa with early opening of the uterine isthmus is associated with high risk of bleeding during pregnancy, and massive haemorrhage during caesarean delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3353045" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cervical cerclage for the temporary treatment of patients with placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9704776" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cervical cerclage: an alternative for the management of placenta previa?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30081730" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The role of cervical pessary and progesterone therapy in the phenomenon of placenta previa migration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31044098" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cervical Pessary versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women with Placenta Previa: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27183001" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Predictors for Emergency Cesarean Delivery in Women with Placenta Previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8203426" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Placenta previa: antepartum conservative management, inpatient versus outpatient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8178847" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Expectant management of placenta previa: cost-benefit analysis of outpatient treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6731509" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Conservative management of placenta previa: a cost-benefit analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21138515" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Travel time from home to hospital and adverse perinatal outcomes in women at term in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15339764" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Conservative versus extirpative management in cases of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23639121" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Transverse uterine fundal incision for placenta praevia with accreta, involving the entire anterior uterine wall: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30016336" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effect of site of placentation on pregnancy outcomes in patients with placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24480901" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Does previa location matter? Surgical morbidity associated with location of a placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24750257" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Anterior placentation as a risk factor for massive hemorrhage during cesarean section in patients with placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21814478" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Maternal outcomes according to placental position in placental previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28107460" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The Incidence of Postpartum Hemorrhage in Pregnant Women with Placenta Previa: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22795757" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Temporary treatment of severe postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24147797" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Tourniquet device for hemorrhage control during cesarean section of complete placenta previa pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30443434" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Use of a Fibrin Sealant Patch at Cesarean for Conservative Management of Morbidly Adherent Placenta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19945698" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : B-Lynch suture, intrauterine balloon, and endouterine hemostatic suture for the management of postpartum hemorrhage due to placenta previa accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21722873" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Multiple square sutures for postpartum hemorrhage: results and hysteroscopic assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15511932" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Massive haemorrhage due to placenta praevia accreta: a useful role for vasopressin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24750470" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Local injection of vasopressin reduces the blood loss during cesarean section in placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31917139" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23828423" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Endouterine hemostatic square suture vs. Bakri balloon tamponade for intractable hemorrhage due to complete placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33421119" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The routine use of prophylactic Bakri balloon tamponade contributes to blood loss control in major placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24506478" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A novel 'uterine sandwich' for haemorrhage at caesarean section for placenta praevia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21501126" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Application of uterine compression suture in association with intrauterine balloon tamponade ('uterine sandwich') for postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30663270" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Vaginal delivery in women with a low-lying placenta: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8008324" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The effect of placenta previa on blood loss in second-trimester pregnancy termination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12698775" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Late midtrimester pregnancy termination in the presence of placenta previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15539869" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Second- and third-trimester therapeutic terminations of pregnancy in cases with complete placenta previa--does feticide decrease postdelivery maternal hemorrhage?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17303496" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effect of placenta previa on blood loss in second-trimester abortion by labor induction using gemeprost.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27853824" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Efficacy and Safety of Prophylactic Uterine Artery Embolization in Pregnancy Termination with Placenta Previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30076600" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effects of prophylactic uterine artery embolization on second-trimester induced abortions in patients with placenta previa.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
